Ignite Creation Date:
2024-05-05 @ 11:08 PM
Last Modification Date:
2024-10-26 @ 10:29 AM
Study NCT ID:
NCT01266265
Status:
COMPLETED
Last Update Posted:
2016-02-17
First Post:
2010-12-22
Brief Title:
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso Compared to Other FDA Approved PAH Therapies
Sponsor:
United Therapeutics
Organization:
United Therapeutics
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Pulmonary Arterial Hypertension |
Keywords:
| Name | View |
|---|---|
| oral treprostinil | View |
| pulmonary arterial hypertension | View |
| PAH | View |
| treprostinil sodium | View |
| Tyvaso | View |
| inhalation | View |
| Ventavis | View |
| iloprost | View |
| prostacyclin | View |
| epoprostenol sodium | View |
| Flolan | View |
| Veletri | View |
| subcutaneous and intravenous prostacyclin analogue | View |
| Remodulin | View |
| oral ERA | View |
| bosentan | View |
| Tracleer | View |
| ambrisentan | View |
| Letairis | View |
| oral PDE5 inhibitors | View |
| sildenafil | View |
| Revatio | View |
| tadalafil | View |
| Adcirca | View |
| Opsumit | View |
| macitentan | View |
| Adempas | View |
| riociguat | View |
| Orenitram | View |